The European Group for Blood and Marrow Transplantation (EBMT) Late-Effects Working Party collected data on patients who survived more than 5 years after BMT. Height at transplant and at the latest followup examination were evaluated in 79/258 subjects who were below the age of 15 at BMT. A significant decrease in height-standard deviation score (SDS) was observed in leukemic children conditioned with total body irradiation (TBI) and in those who received both cranial irradiation and TBI. The majority of these patients, however, received single-dose TBI (28/41). A significant decrease in height-SDS was also seen in children who received thoraco-abdominal irradiation suggesting that the deleterious effect of irradiation on growth after BMT is not entirely due to injury to cranial neuroendocrine structures, but also probably due to damage to bone epiphyses, thyroid and gonads. A non-significant decrease in height was observed in children transplanted using chemotherapy alone. Nutritional status, expressed as body-mass index (BMI), was found unchanged in the adult group (n = 158). A significant increase in BMI was observed in the younger patients (n = 88), which parallels the normal increase in BMI observed during childhood. This suggests that on longterm analysis, a good nutritional status is maintained in patients undergoing BMT at any age. Keywords: bone marrow transplantation; growth; irradiation; leukaemia; nutrition; severe aplastic anaemia During the last two decades bone marrow transplantation (BMT) has become a widely accepted procedure in the treatment of many malignant and non-malignant haematological disorders. Refinements in techniques and greater experience have resulted in an increase in the number of long-term survivors. with short-and long-term side-effects 3-7 such as graft versus-host disease (GVHD), severe acute and chronic infections, and an increased risk for the development of secondary malignancy.
Summary:
The European Group for Blood and Marrow Transplantation (EBMT) Late-Effects Working Party collected data on patients who survived more than 5 years after BMT. Height at transplant and at the latest followup examination were evaluated in 79/258 subjects who were below the age of 15 at BMT. A significant decrease in height-standard deviation score (SDS) was observed in leukemic children conditioned with total body irradiation (TBI) and in those who received both cranial irradiation and TBI. The majority of these patients, however, received single-dose TBI (28/41). A significant decrease in height-SDS was also seen in children who received thoraco-abdominal irradiation suggesting that the deleterious effect of irradiation on growth after BMT is not entirely due to injury to cranial neuroendocrine structures, but also probably due to damage to bone epiphyses, thyroid and gonads. A non-significant decrease in height was observed in children transplanted using chemotherapy alone. Nutritional status, expressed as body-mass index (BMI), was found unchanged in the adult group (n = 158). A significant increase in BMI was observed in the younger patients (n = 88), which parallels the normal increase in BMI observed during childhood. This suggests that on longterm analysis, a good nutritional status is maintained in patients undergoing BMT at any age. Keywords: bone marrow transplantation; growth; irradiation; leukaemia; nutrition; severe aplastic anaemia During the last two decades bone marrow transplantation (BMT) has become a widely accepted procedure in the treatment of many malignant and non-malignant haematological disorders. Refinements in techniques and greater experience have resulted in an increase in the number of long-term survivors. with short-and long-term side-effects 3-7 such as graft versus-host disease (GVHD), severe acute and chronic infections, and an increased risk for the development of secondary malignancy. [8] [9] [10] [11] The paediatric group of patients who have survived BMT are of interest because of the dynamic biological processes of growth and development. Children are still growing physically and emotionally and therefore, they are more susceptible to damage that might be induced by radio-and chemotherapy used during BMT. [12] [13] [14] [15] [16] [17] This report is derived from a more extensive retrospective study on late-effects, gathered by means of a questionnaire sent by the EBMT Late-Effects Working Party to all BMT centres in Europe. 18, 19 It evaluates the effect of BMT on growth and on the nutritional status of patients who underwent transplantation during childhood.
Patients and methods
The European Group for Blood and Marrow Transplantation (EBMT) Late-Effects Working Party collected data by means of a questionnaire, investigating late toxicity in long-term survivors after BMT. Data and patient characteristics have already been reported. 18, 19 Twenty-eight centres (the participating Centres are acknowledged in the Appendix) reported data on a total of 258 patients who have survived more than 5 years. Ninety-one of the 258 were transplanted before 31 December 1980 and have therefore survived for more than 10 years after transplant at the time of the collection of data, while the remaining 167 were transplanted during 1984, and have survived for at least 5 years after transplantation.
This study analyses the effect of transplantion on growth and nutrition on the 89 patients (53 boys; 36 girls) who were under the age of 15 years at the time of BMT. Data relating to height, weight, bone-age, secondary sexual characteristics and date of onset of menarche were collected at the time of transplant and at last follow-up examination. We also requested information on endocrinological parameters such as gonadotropin levels, thyroid and pituitary function tests and the presence of osteoporosis, but these data were insufficient for analysis.
Growth (children only)
Height measurements were expressed as a standard deviation score (SDS) from the mean of the general population. SDS provides a method for relating a patient's height to that of age peers. It was calculated as the actual measurement minus the mean height of children of the same age and of the same sex divided by the standard deviation of the normal population of the same age and sex. 20 The SDS was used in order to eliminate the effect of sex and age on the measurement of height. The normal value of SDS for the general population is between −2.0 and +2.0 SDS.
Ten of the 89 patients had incomplete data and were excluded from the growth subset of the study. The remaining 79 patients were divided into four groups according to their haematological disease and the conditioning regimen used.
SAA-no irradiation group:
Twenty-seven patients were transplanted for severe aplastic anaemia (SAA) using cyclophosphamide as the preparative regimen. These patients did not receive irradiation. Mean age (±SD) at transplantation was 8.1 ± 2.9 (range 0.9-13.3) years, and the mean period of follow-up was 9.2 ± 3.1 years for this group.
SAA-TAI group:
Eleven children were transplanted for SAA with a conditioning regimen which included thoracoabdominal irradiation (TAI) thus sparing the neuroendocrine structures. TAI was given as a single dose of 900 cGy. The mean age at transplant was 10.9 ± 3.0 (range 4.2-14.9) years, and the mean period of follow-up was 5.9 ± 0.6 years.
Leukaemia-TBI group: Twenty-three children were transplanted for leukaemia with a conditioning regimen which included total body irradiation (TBI). Single-dose TBI was given to 19 children at a mean dose of 920 ± 96 cGy (range 711-1000), and the remaining four patients received 3-6 fractions of a total of 1035 ± 180 cGy (range 800-1260). The mean age at transplantation was 8.6 ± 3.7 (range 2.1-14.4) years, and the mean time of follow-up was 7.2 ± 2.4 years.
Leukaemia-CRT group:
Eighteen children were transplanted for ALL and received CRT during first-line treatment. Transplant conditioning included TBI (nine received single-dose TBI at a mean dose of 920 ± 96 cGy; nine received 2-6 fractions at a mean dose of 1035 ± 180 cGy). The mean age at transplantation was 9.8 ± 3.1 (range 5.6-14.9) years, and the mean time of follow-up was 5.9 ± 1.4 years.
Age at BMT, and follow-up interval from transplant to latest evaluation were similar in all four groups studied (one-way ANOVA analysis). The variation in height SDS (Delta SDS = (latest SDS) − (SDS BMT)) was calculated for each group and for the total population of 79 children with validated data. A positive delta-SDS value was considered as gain in height while a negative value expressed loss in height between the two time points.
Nutritional status (all patients)
Body mass index (BMI = Wt/Ht 2 ) was calculated from the height and weight measurements of patients and was used as an index of their nutritional status. 21 BMI is known to continuously increase until the age of 18 22 when it reaches a steady state (normal range for the adult population is 20-27). Therefore, patients were divided into two groups, ie a paediatric group who were transplanted before the age of 15 years, and an adult group who were transplanted after the age of 15 years. The mean age for the paediatric group was 8.7 ± 3.8 years (range 0.2-14.8) and for the adult group was 27.6 ± 8.3 years (range 15.1-50.0). BMI data were available in 246/258 patients at the time of BMT, and in 238/258 patients at the time of last follow-up.
Statistical analysis
The difference between height-SDS and BMI at the two time points, ie at BMT and latest follow-up, were compared within each group using the non-parametric Wilcoxon test.
The effect of age at BMT, gender, type of irradiation, dose rate and fractionation, and acute or chronic GVHD on growth and nutritional status outcome were also evaluated using a stepwise factor analysis.
Results

Growth (Table 1)
Analysing the whole group of 79 patients, a significant decrease of height SDS was observed (pre-BMT height-SDS 0.18 ± 1.46 compared with height-SDS at latest examination of −0.77 ± 1.67; paired Student's t-test P Ͻ 0.0001).
There was a significant decrease in height-SDS in the three groups of patients who received irradiation as part of their conditioning regimen, ie the SAA-TAI group (mean loss of 1.27 ± 1.51 SDS; Wilcoxon signed-rank test between pre-and post-BMT height SDS, P Ͻ 0.008), the leukaemia-TBI group (mean loss of 1.11 ± 0.73 SDS; Wilcoxon signed-rank test P Ͻ 0.0004), and the leukaemia-CRT group (mean loss of 1.46 ± 1.01 SDS; Wilcoxon signed-rank test P Ͻ 0.00004). A slight, although not statistically significant decrease in height-SDS (mean loss of 0.44 ± 1.48 SDS; Wilcoxon signed-rank test not significant) was also observed in the SAA-no irradiation group, where only chemotherapy was used for pre-BMT conditioning (Table 1) . Delta-SDS was not significantly different among the three irradiation groups (the TBI, CRT and the TAI groups).
Age at BMT, gender, irradiation dose-rate and number of fractions, and occurrence of acute or chronic GVHD did not significantly affect growth.
Nutritional status-BMI (Table 2)
A significant increase in BMI value was observed in the total cohort of patients (from 20.43 ± 4.17 at the time of BMT to 21.36 ± 3.82 at the last follow-up examination; paired t-test P Ͻ 0.02). When the adult population was con- sidered alone, the BMI value remained unchanged (paired t-test analysis) in 151 adult patients (22.24 ± 3.33 at BMT and 22.35 ± 3.57 at the last examination). The paediatric population, however, showed a significant increase in BMI values from 17.27 ± 3.60 to 19.57 ± 3.64 (paired t-test analysis P Ͻ 0.0001). The pattern of variation of BMI values among groups was not statistically different.
Discussion
Impairment of growth and development in patients who underwent BMT during childhood might be the result of a number of factors related both to the primary disease and its treatment, and also to the procedure of transplantation which requires intensive pre-BMT conditioning therapy (irradiation and/or immunosuppressive therapy) in order to guarantee eradication of disease and adequate engraftment of the marrow cells. Moreover, BMT is frequently followed by immediate complications such as infection and GVHD which often require administration of large doses of immunosuppressive agents (corticosteroids, cyclosporine A, azathioprine). All these factors may be responsible for long-term complications which in the transplanted child, may especially include alterations in growth pattern. In 1981 and 1984 BMT was a complex and life-saving procedure, of relatively recent practice. Therefore, quality of life and/or possible side-effects were secondary considerations compared to the achievement of a better survival rate. This explains the paucity of endocrinological laboratory evaluations on these patients and why we chose to examine simple parameters available from the questionnaire.
In the present study, growth was found to be significantly impaired in children in whom irradiation was used (leukaemia-CRT, leukemia-TBI and SAA-TAI groups). It is of note, however, that 28 of the 41 patients who received TBI (TBI and CRT groups) were transplanted during a period when TBI was given as a 10 Gy single-dose and not fractionated or hyperfractionated as is recommended by the more recent protocols. There was a small but non-significant decrease in height-SDS in children with SAA who received chemotherapy alone as their preparative regimen. This suggests that irradiation is a major contributor to loss of growth after BMT. Nevertheless, other factors may also play a role. Indeed Sklar et al 23 have shown that the final height of non-transplanted ALL patients who received chemotherapy alone was lower than predicted. A similar observation was reported by Wingard et al 17 and by Sanders. 15 The decrease in growth observed in this study in the SAA-TAI group (delta-SDS = 0.9 ± 0.91; P Ͻ 0.02) although less marked than that in the leukaemia-TBI and CRT groups, is of particular interest since these patients received irradiation to the thoraco-abdominal regions and to the arms and forearms only, whilst the cranium was outside the irradiation field. The hypothalamus and pituitary gland were therefore spared and the decreased growth cannot be explained simply by impaired secretion of growth hormone. Furthermore, the loss of growth cannot be explained by factors inherent in severe aplastic anaemia, as patients with SAA who did not receive TAI did not experience a significant decrease in height-SDS. The reduction in growth observed in the SAA-TAI group may therefore be explained by the direct effect of irradiation on gonadal function with subsequent reduction in pubertal growth and/or by damage to the bone epiphyses. Our data suggest, therefore, that growth impairment in patients after BMT is probably due to a combination of factors.
BMI values in the adult group were within the normal range for the general adult population, both at the time of BMT and at the latest follow-up examination. 21 This suggests that, on a long-term basis, surviving patients maintained a good nutritional status after transplantation. When the whole cohort (adults and children together) was considered, a significant increase in BMI values was observed. However, this was the result of a significant increase in the BMI value of the paediatric group only. The increase in BMI in the paediatric group parallels the change in BMI normally seen during childhood and adolescence. 22 This suggests that good nutritional status was also maintained in patients transplanted as children, despite this being a critical period for growth and development. In summary, irradiation has a deleterious effect on growth even when neuroendocrine structures are spared, suggesting that the reduction in growth was a result of a number of factors including endocrine dysfunction, damage to bone epiphyses, and impairment of gonadal function. The slight decrease in height-SDS seen in the nonirradiated patients may be explained by the lesser effect of chemotherapy on those organs and/or by an inherent property of the diseases requiring treatment by transplant. In contrast, malnutrition and malabsorption do not seem to be a cause for growth delay in paediatric patients, and are not an important late effect of the BMT procedure in adults.
